About CRI

Children’s Research Institute conducts and promotes translational and clinical medical research and education programs that lead to improved understanding, prevention, treatment, and care of childhood diseases.

Education

The Office of Medical Education is responsible for providing an organized education program for residents and fellows to ensure safe and appropriate care for patients.

CTSI-CN

The Clinical Translational Science Institute fosters broad collaborative innovation that improves child, family, and community health.

Our Centers and Institutes

Cancer & Immunology Research

Developing the best and most compassionate care for children with cancer, infectious diseases, and immune system disorders.

Genetic Medicine Research

We strive to transform children’s health through genome-enabled research, pre-clinical studies of experimental therapeutics, and clinical trials. We use this knowledge to restore health and prevent illness in childhood and throughout life.

Neuroscience Research

Our vision is to understand the development of the central nervous system and the cellular, molecular, synaptic, and network mechanisms of brain dysfunction to prevent or treat neurological, developmental, and behavioral disorders of childhood.

Translational Science

We work to improve the prevention and treatment of childhood diseases through scientific discoveries into preventative and therapeutic applications that address disease processes and disease-related issues.

Research Funding by Sponsor

Research Funding by Sponsor

Services and Support

Children’s Research Institute provides a centralized administrative infrastructure to support the research community and to ensure compliance with federal, local, and private sponsor regulations as well as terms and conditions.

Latest News

Researchers Uncover Novel Blood Biomarkers To Better Monitor Therapy Effectiveness for Duchenne Muscular Dystrophy

Children's National Health System researchers and other teams have uncovered a wide range of blood biomarkers in patients with Duchenne Muscular Dystrophy (DMD) that may provide significant insights into evaluating stages of the rare and deadly disease, and create the opportunity for future drug development to combat it.